Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Researchers at Columbia University Irving Medical Center have identified the specific neurons in mice brains that tell them ...

The Post-Bariatric Hypoglycemia market growth is driven by factors like increase in the prevalence of Post-Bariatric ...

12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 ...

“We believe the data from this study will demonstrate that the combination of MC4R + GLP-1 ... GLP-1/GIP therapy. Additional trial information can be found at https://clinicaltrials.gov via the ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product sales increased ... sales were up 91% to DKK 21.4 billion. Wegovy sales continued ...